Login  

 

The article you requested is

Dietary Restrictions and Drug Interactions With Monoamine Oxidase Inhibitors: An Update

J Clin Psychiatry 2012;73(suppl 1):17-24
10.4088/JCP.11096su1c.03

Monoamine oxidase inhibitors (MAOIs) are effective treatments for depression that has atypical features or that has failed to respond to other antidepressants. However, MAOIs are underused because clinicians are concerned about dietary and drug interactions with this class of medication. Hypertensive crisis and serotonin syndrome can occur in rare cases due to interactions between MAOIs and foods containing tyramine as well as interactions with serotonergic and sympathomimetic agents. A better understanding of the foods and drugs that can cause adverse reactions, as well as knowledge of newer MAOIs with mechanisms of action and delivery methods that reduce these risks, may help clinicians to consider the use of these medications, when appropriate, in their patients with depression.

(J Clin Psychiatry 2012;73[suppl 1]:17–24)

From the Indiana Institute for Personalized Medicine and the Division of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis.

This article is derived from the planning teleconference series “A Fresh Look at Monoamine Oxidase Inhibitors for Depression,” which was held December 2011 through February 2012 and supported by an educational grant from Mylan Specialty L.P. (formerly known as Dey Pharma, L.P.).

Dr Flockhart has no personal affiliations or financial relationships with any commercial interest to disclose relative to this article.

Corresponding author: David A. Flockhart, MD, PhD, Indiana University School of Medicine, Wishard Memorial Hospital, 1001 West 10th St, Indianapolis, IN 46202 (dflockha@iupui.edu).